Professionals 223 Users Online

Intravenous Immunoglobulin Market

Market Study on Intravenous Immunoglobulin Industry - Treatment for Immunodeficiency Diseases to comprise 1/5th of Total Usage

Intravenous Immunoglobulin (IVIg) Market Segmented By Types - IgG | IgM | IgA | IgE | IgD

Intravenous Immunoglobulin Market Snapshot (2022-2032)

The global intravenous immunoglobulin market is likely to reach a market value of US$ 12,000 Million in 2022 and is expected to accumulate a market value of US$ 25,884 Million by registering a CAGR of 7.9% in the forecast period 2022-2032. Growth of the intravenous immunoglobulin market can be attributed to the fact that it is the only available treatment option for treatment. The market for intravenous immunoglobulin registered a CAGR of 5% in the historical period 2016-2021

“Sedentary lifestyle habits, including consumption of saturated fats, salt, and sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. The rising prevalence of lifestyle-associated disorders such as obesity and antibody deficiency disorders is expected to fuel the growth.”

The growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of intravenous immunoglobulin (IVIG) treatments, and rising use of off-label indications are the key drivers of the market. The rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations.

Attributes

Details

Intravenous immunoglobulin Market CAGR (2022-2032)

7.9%

Intravenous immunoglobulin Market Size (2022)

US$ 12,000 Million

Intravenous immunoglobulin Market (2032)

US$ 25,884 Million

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

What are the Factors Propelling the Growth of Intravenous Immunoglobulin Market?

Chronic inflammatory diseases boosting growth of intravenous immunoglobulin market

The global IVIG market is expanding rapidly because of an increasing number of patients with bleeding issues and an increasing number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients. Furthermore, increased investment in the healthcare industry is assisting in the growth of the IVIG market. Additionally, the growing number of patients suffering from autoimmune illnesses and other pathological conditions is fueling market expansion for IVIG products.

The COVID-19 pandemic, which is currently in its last stages, is expected to drive the global market. According to a December 2020 research called "COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience, 70 percent of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus, and 59 percent were admitted to hospitals, with 8 percent dying. As a result, because immunocompromised people are more likely to get COVID-19, the market for intravenous immunoglobulin therapy is predicted to expand during the pandemic.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What are the Prevailing Opportunities in the Intravenous Immunoglobulin Market?

Availability of Various Therapies shaping landscape for Intravenous Immunoglobulins

Aside from the economic crisis, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. An uncommon but deadly illness known as MIS-C (multi-system inflammatory syndrome) has been documented in numerous places among the younger population. Many medical professionals have been evaluating the efficacy of IVIG injection for COVID-19 patients.

According to the W.H.O, currently, there are over 50 different Primary Immune Deficiencies (PIDs) such as specific antibody deficiency and X-lined hypo-gamma-globulinemia. PIDs include 176 different types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health, approximately 6 million patients are suffering from PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What are the Factors Hampering the Intravenous Immunoglobulin Market?

Lack of awareness and expensive nature of treatment affecting market growth

Lack of awareness amongst patients is restraining the growth of the overall market. This is owing to the ignorance of the effects of infections and the lack of inclination towards taking proper treatments. Furthermore, the rising cost of IVIG therapy is projected to be a significant barrier to market expansion. Immunoglobulin infusions are typically given once every 3 to 4 weeks, and the therapy is ongoing around 12-16 sessions yearly.

The estimated cost of IVIG is USD 73.89 per gram, with a total cost of USD 10,000 depending on the severity of the illness. Immunoglobulin replacement treatments are long-term therapies that typically last 6 months. As per the ABIM Foundation, the expense of IgG treatment therapy exceeds US$ 30,000 a year.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Comparative View of Adjacent Intravenous Immunoglobulin Market

Attributes

Intravenous immunoglobulin Market

CAGR (2022-2032)

9.7%

Market Value (2032)

US$ 25,884 Million

Growth Factor

The increasing need for internal network security due to the rising incidences of cyberattacks is expected to drive the market in the forecast period.

Opportunity

Adoption of the advanced network management system is expected to offer lucrative opportunities to the market.

Comparative View of Adjacent Immunoglobulin Market

Attributes

Immunoglobulin Market

CAGR (2022-2032)

10%

Market Value (2032)

US$ 22,955 Million

Growth Factor

Increasing prevalence of immunodeficiency due to changing lifestyles is expected to drive the growth of the immunoglobulins market.

Opportunity

Increasing demand for immunoglobulins due to fewer side effects and increased bioavailability due to the biological origin is expected to offer lucrative opportunities to the market.

Category-Wise Insights

Convenience of Products and Availability of Treatments Increasing Inclination Towards Hospitals for Intravenous Immunoglobulin Market?

Quick Reimbursements and treatment making hospitals a viable option

The growing incidence of primary immune deficiencies, hepatitis C, and other diseases has resulted in an increment in the number of hospitalizations worldwide, expanding the customer preference for hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies.

The hospital pharmacy segment is expected to dominate the market with a revenue share of over 57% in 2022 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies.

Primary and Acquired Immunodeficiency Diseases Attracting Growth for Intravenous Immunoglobulin Market?

IV antibiotics spurring adoption of Intravenous Immunoglobulin

In 2022, immunodeficiency diseases are expected to dominate the market with a revenue share of over 20% owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. Hence, the business is expected to witness steady growth in the coming years.

The chronic inflammatory demyelinating polyneuropathy segment is expected to hold the second-largest share in 2022. It is usually found in patients with diabetes mellitus. The treatment of CIDP involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods. The associated benefits such as safety, minimally invasive, and user-friendly treatment option are contributing to the growth of the industry.

Hypogammaglobulinemia is expected to account for the third-largest revenue share in 2022. This can be attributed to the increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

The Kawasaki disease segment is expected to witness lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years. Moreover, factors such as increasing patient awareness levels and rising incidence of antibody deficiency diseases are expected to boost the demand for IVIG therapy, consequentially driving the segment.

Which are the Key Regions in the Intravenous Immunoglobulin Market?

Regions

CAGR

United States

5%

Canada

4.5%

China

5%

Japan

4%

India

4.5%

Administration of IVIG Therapies Creating Lucrative Opportunities for Intravenous Immunoglobulin Market in North America?

Healthcare expenditure boosting dependency on Intravenous Immunoglobulin treatments

The increasing level of awareness pertaining to products involved in the treatment of immunodeficiency diseases, rising inclination of clinicians towards these therapies, and growing healthcare expenditure are the key factors contributing to the market growth.

Changing lifestyles and the rising geriatric population prone to chronic diseases are some of the factors contributing to the growth of this industry. In addition, increasing incidences of PID are expected to present this market with future growth opportunities. In the U.S., autoimmune illnesses are the third most prevalent cause of chronic illnesses. Since many autoimmune disorders are uncommon, the National Institutes of Health predicts that diseases affect between 5% and 8% of the U.S. population. Autoimmune illnesses are becoming more common for unclear causes. The number is expected to grow over the forecast period.

Furthermore, the growing administration of IVIG therapies for the treatment of illness, the existence of established healthcare as well as research infrastructure, and the rapidly increasing number of product approvals from the U.S. FDA are some of the factors anticipated to contribute to the regional market growth. Thus, North America is expected to possess 47% market share for intravenous immunoglobulin in 2022.

Increasing Awareness of Treatments favoring Growth of Intravenous Immunoglobulin Market in Asia Pacific?

Rising incidences of immune disorders accelerating growth of market

Asia Pacific is anticipated to exhibit a lucrative growth rate over the forecast period as a consequence of the increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies, coupled with a growing geriatric population. Other factors contributing to the growth of this business are emerging economies, growing healthcare spending, and the rapidly growing immunoglobulin market.

In addition, rising incidences of immune disorders, awareness levels pertaining to intravenous and subcutaneous immunoglobulin therapies, and improving healthcare facilities are anticipated to fuel further growth in the near future. Thus, Asia Pacific is expected to possess 35% market share for intravenous immunoglobulin in 2022.

Market Competition

This intravenous immunoglobulin industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business.

  • In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
  • On 25 April 2022, Grifols S.A. completed its purchase of Biotest, a significant and transformative deal that will boost growth and innovation. Grifols' purchase of Biotest AG allows it to accelerate and extend its product range, boost patient access to plasma medicines, operate the biggest private European network of plasma facilities (87 sites), and boost revenue growth and margin development.

Report Scope

Attribute

Details

Forecast Period

2022-2032

Historical Data Available For

2017-2021

Market Analysis

USD Million for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Market Segments Covered

  • Type
  • Application
  • Distribution Channel
  • End User
  • Region

Key Companies Profiled

  • Biotest AG
  • Baxter International Inc.
  • Octopharma AG
  • LFB Biotechnologies
  • Grifols SA
  • Argenx
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrian Biopharma
  • BDI Pharma Inc.
  • Pfizer Inc.

Customization & Pricing

Available upon Request

Intravenous Immunoglobulin Industry Research by Category

By Type

  • IgG
  • IgM
  • IgA
  • IgE
  • IgD

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain-Barre Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Biotest AG
  • Baxter International Inc.
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc.
  • Pfizer Inc.

- Frequently Asked Questions -

The global intravenous immunoglobulin market is estimated at a 7.9% growth rate during the forecast period of 2022-2032.

The global intravenous immunoglobulin market is expected to garner US$ 25,884 Million by 2032.

U.S is expected to register a CAGR of 5% from 2022-2032.

Japan is expected to register a CAGR of 4% in the forecast period.

The Global intravenous immunoglobulin market was estimated at US$ 11,215 Million in 2021.

The hospital pharmacy segment is expected to dominate the market with a revenue share of over 57% in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate